Group 1 - Structure Therapeutics (GPCR) released new topline data from the Phase 2 ACCESS II trial, resulting in a stock increase of approximately 5% [1] - The initial data from the trial is viewed positively, supporting a bullish outlook for the company [1] Group 2 - The focus is on identifying promising biotechnology companies that innovate through unique mechanisms of action, first-in-class therapies, or platform technologies [1] - The analysis emphasizes evaluating the science behind drug candidates, the competitive landscape, clinical trial design, and potential market opportunities while balancing financial fundamentals and valuation [1]

PresentationGood morning, and welcome to the Structure Therapeutics Conference Call. [Operator Instructions] Please be advised that this conference call is being recorded. I would now like to turn the call over to Corey Davis of LifeSci Advisors.Corey DavisLifesci Advisors, LLC Thank you, Dan, and good morning, everyone. Earlier today, we issued a press release providing top line results from the ACCESS II clinical program for aleniglipron, our oral small molecule GLP-1 receptor agonist. A copy of this rele ...

Core Insights - Structure Therapeutics' GLP-1 pill demonstrated significant efficacy, helping patients achieve over 16% weight loss in a midstage trial, surpassing results from competing obesity medications [1] Company Summary - Structure Therapeutics is advancing its GLP-1 pill, which has shown promising results in clinical trials, indicating a strong potential for market competitiveness in the obesity treatment sector [1] Industry Summary - The obesity drug market is becoming increasingly competitive, with Structure Therapeutics' recent trial results highlighting the effectiveness of its GLP-1 pill compared to existing options [1]

Summary of Structure Therapeutics Conference Call on Aleniglipron Company Overview - **Company**: Structure Therapeutics (NasdaqGM:GPCR) - **Product**: Aleniglipron, an oral small molecule GLP-1 receptor agonist Key Industry Insights - **Clinical Program**: ACCESS II clinical program for aleniglipron - **Market Context**: Addressing the global obesity pandemic, with an estimated 1 billion people living with obesity by 2030 Core Findings and Data - **Efficacy Results**: - ACCESS II study showed a placebo-adjusted mean weight loss of **15.3%** at doses of **180 mg** and **240 mg** after **36 weeks** [5][8] - At **44 weeks**, the mean weight loss was **16.3%** for **180 mg** and **16%** for **240 mg** with no signs of plateauing [8][29] - In the ACCESS open label extension, participants on **120 mg** experienced a body weight loss of up to **16.2%** after a median follow-up of **20 weeks** [7][29] - **Safety and Tolerability**: - Overall adverse event (AE)-related treatment discontinuation rate was **2%** in the ACCESS open label extension [9][22] - No events of drug-induced liver injury or QTc prolongation were reported across all studies [9][28] - The gastrointestinal tolerability profile improved with a starting dose of **2.5 mg**, showing a lower incidence of AEs compared to higher starting doses [9][26] - **Dosing Strategy**: - The strategy of starting low at **2.5 mg** and titrating slowly was emphasized as effective in optimizing tolerability while achieving weight loss [11][57] - Participants showed early signs of weight loss, achieving **6.4% to 6.8%** weight loss after a median follow-up of **20 weeks** when starting at **2.5 mg** [29] Additional Insights - **Future Studies**: Structure Therapeutics plans to share more data from four additional studies throughout **2026**, including type 2 diabetes and body composition studies [32] - **Regulatory Plans**: An end of phase 2 meeting with the FDA is scheduled for **Q2 2026**, with plans to initiate phase 3 in the second half of the year [32] - **Pipeline Expansion**: The company is developing an amylin program with two molecules, ACCG-2671 and ACCG-3535, to complement the GLP-1 program [33] Competitive Landscape - **Differentiation**: Aleniglipron is positioned as a potentially best-in-class oral GLP-1 with a strong safety profile, scalability, and combinability with other treatments [34][77] - **Market Need**: The company emphasizes the need for oral small molecules to meet the demand of over **100 million** people in the U.S. living with obesity [35] Conclusion - Structure Therapeutics presents compelling evidence for aleniglipron's efficacy and safety, positioning it as a significant player in the obesity treatment market. The ongoing studies and strategic plans indicate a strong commitment to addressing the global obesity crisis with innovative solutions.

Core Insights - The company reported significant weight loss results from its investigational oral drug, aleniglipron, designed for treating obesity, contributing to a rise in stock price while broader markets showed mixed movements [1] Group 1: Clinical Trial Results - Aleniglipron achieved a placebo-adjusted mean weight loss of 16.3% (39 lbs) at the 180 mg dose and 16.0% (37 lbs) at the 240 mg dose after 44 weeks, with no evidence of a weight loss plateau [2] - Interim data from the ongoing ACCESS Open Label Extension study showed continued weight loss of up to 16.2% (40.5 lbs) with the 120 mg dose at 56 weeks, demonstrating the drug's efficacy and favorable safety profile [2][3] Group 2: Regulatory and Development Plans - The company plans to hold an FDA end-of-Phase 2 meeting in Q2 2026, with Phase 3 initiation on track for the second half of 2026 [4] - The trial is designed with a starting titration dose of 2.5 mg, intending to evaluate multiple doses up to 240 mg [4] Group 3: Competitive Advantages - CEO Raymond Stevens highlighted four factors that could make aleniglipron competitive, including its efficacy, with a higher dose leading to weight loss of up to 15.3% at 36 weeks [5] - The drug's manufacturing cost is favorable as a small-molecule pill, allowing for efficient production at scale for the U.S. market [6] - Aleniglipron can be combined with other therapies, showing synergistic effects when paired with an amylin-targeting drug [6] Group 4: Stock Performance and Technical Indicators - The stock is currently trading 6.5% below its 20-day simple moving average (SMA) but 1.3% above its 100-day SMA, indicating short-term weakness while maintaining longer-term strength [7] - Over the past 12 months, shares have increased by 146.67%, positioned closer to their 52-week highs than lows [7] Group 5: Analyst Consensus and Market Position - The stock carries a Buy Rating with an average price target of $101.20, indicating positive analyst sentiment [9] - Recent analyst actions include a Buy rating from HC Wainwright & Co. with a target raised to $114.00 [10]

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral GLP-1RAs and comparable efficacy to injectable GLP1-RAs Continued weight loss up to 16.2% (40.5 lbs) observed with 120 mg dose in the ACCESS Open Label Extension (OLE) study at 56 weeks, with no evidence of weight loss plateau Updated interim data from ACCESS OLE and Body Composition studies continue to support ...

Company Overview - Structure Therapeutics Inc. is a clinical-stage biotechnology company focused on developing innovative oral therapeutics for chronic diseases, particularly targeting significant unmet medical needs [2][3] - The company specializes in G-protein-coupled receptor (GPCR) drug discovery, with a pipeline led by GSBR-1290 aimed at treating type-2 diabetes and obesity, as well as candidates for pulmonary and cardiovascular diseases [2] Financial Performance - As of the end of 2025, Structure Therapeutics reported a net loss of $141.2 million, with research expenditures reaching $225.3 million to advance its GLP-1 franchise, which is typical for companies preparing for late-stage trials [9] - The company ended 2025 with $1.4 billion in cash and investments, which is expected to fund operations through the end of 2028 [8] Stock Performance - Structure Therapeutics' shares were priced at $71.41 as of February 17, 2026, reflecting a 214.3% increase over the past year, significantly outperforming the S&P 500 by 180.87 percentage points [4] - Casdin Capital sold 380,000 shares of Structure Therapeutics during the fourth quarter, valued at approximately $15.52 million based on the average share price for that period [5][6] Clinical Developments - The company reported promising data from its Phase 2 ACCESS programs, showing placebo-adjusted weight loss of up to 15.3% at 36 weeks with higher doses of aleniglipron, with no plateau observed [8] - A 44-week readout is anticipated in the first quarter of 2026, and the initiation of Phase 3 trials is planned for the second half of 2026 [8] Market Position - Structure Therapeutics aims to provide differentiated treatment options that enhance both efficacy and patient convenience, positioning itself competitively within the evolving biopharmaceutical landscape [1]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Transition Period From To Commission file number: 001-41608 Structure Therapeutics Inc. (Exact name of registrant as specified in its charter) | Cayman Islands 98-1480821 | | --- ...

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS II study with higher doses expected in Q1 2026 Exhibit 99.1 Aleniglipron Phase 3 initiation expected in 2H 2026 Initial data from the ongoing Phase 1 study of oral small molecule amylin receptor agonist ACCG- ...

Core Insights - Structure Therapeutics has reported positive results from the aleniglipron Phase 2 ACCESS programs, showing significant weight loss of up to 15.3% at 36 weeks [1][7] - The company is well-positioned to capture market share in the obesity treatment sector with its novel oral small molecule therapeutics [2] - Structure Therapeutics has a strong financial position with $1.4 billion in cash and equivalents, expected to fund operations through the end of 2028 [1][9] Clinical Development - Aleniglipron, an oral small molecule GLP-1 receptor agonist, is advancing to Phase 3 clinical development, with initiation expected in the second half of 2026 [1][5] - The upcoming 44-week data from the ACCESS II study is anticipated in Q1 2026, which will provide a more comprehensive profile of aleniglipron [2][4] - Initial data from the ongoing Phase 1 study of ACCG-2671 and the Phase 1 initiation of ACCG-3535 are expected in the second half of 2026 [1][15] Financial Performance - Research and Development (R&D) expenses for Q4 2025 were $68.7 million, up from $33.5 million in Q4 2024, reflecting increased clinical trial costs and personnel expenses [10] - General and Administrative (G&A) expenses for Q4 2025 were $17.6 million, compared to $13.6 million in Q4 2024, primarily due to increased employee expenses [11] - The company reported a net income of $33.0 million for Q4 2025, contrasting with a net loss of $36.5 million in Q4 2024 [14] Market Position - The obesity market is increasingly favoring new oral treatment options, and Structure Therapeutics aims to leverage this trend with its innovative therapies [2] - The company has completed a $748 million financing, strengthening its financial position to advance its clinical programs [2] - Structure Therapeutics is developing a broad portfolio of oral small molecules, including amylin receptor agonists, to address unmet medical needs in metabolic diseases [16][17]